Symbiotec Pharmalab IPO
UpcomingMainboardOpens 24 August 2026Closes 27 August 2026
Symbiotec Pharmalab Limited (incorporated in 2002) is an established research-driven pharmaceutical and biotechnology company specializing in the development and manufacturing of Active Pharmaceutical Ingredients…
Symbiotec Pharmalab Limited (incorporated in 2002) is an established research-driven pharmaceutical and biotechnology company specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), particularly corticosteroids and steroidal-hormone APIs, alongside contract development and manufacturing (CDMO) services and complex injectables. The company operates industrial-scale manufacturing facilities at Rau and Pithampur SEZ in Madhya Pradesh with US FDA, EU-GMP, and WHO-GMP approvals, alongside newly commissioned biomanufacturing facilities in Ujjain and dedicated complex injectables facilities in Mhow. As of March 31, 2026, Symbiotec served over 200 customers across more than 40 countries, holding 43 US FDA Drug Master Files (DMFs) and 23 European Certificates of Suitability (CEPs).
Show moreShow less
Key ratios
As per RHP / filingsTimeline
IPO Opens
24 Aug
IPO Closes
27 Aug
Allotment
28 Aug
Listing
1 Sept
IPO Timeline & Listing Details
| Event | Date |
|---|---|
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Allotment Date | 28 August 2026 |
| Listing Date | 1 September 2026 |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,820 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,92,660 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,07,480 |
SHNI (Max)Below ₹10,00,000 | 67 | ₹9,92,940 |
BHNIAbove ₹10,00,000 | 68 | ₹10,07,760 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 50.00% |
| NII (Non-Institutional Investor) | 15.00% |
| SHNI (Small Non-Institutional Investor) | 5.00% |
| BHNI (Big Non-Institutional Investor) | 10.00% |
| Retail | 35.00% |
| Total | 100.00% |
IPO Objectives
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company (₹112.50 Cr).
- General corporate purposes.
Strengths
- Global leadership position in volume terms in corticosteroid and steroidal-hormone APIs (e.g., Hydrocortisone, Testosterone, Methylprednisolone).
- Fully invested, vertically integrated manufacturing infrastructure with clean regulatory track records across US FDA, EU-GMP, and WHO-GMP.
- Established long-standing relationships with leading multinational and domestic pharmaceutical companies across 40+ countries.
- Strong in-house R&D capabilities spanning complex chemical synthesis, biotransformation, and fermentation technologies.
Weaknesses
- High product concentration risk, with API sales contributing 96.07% and top 5 products accounting for 62.27% of FY26 revenue.
- Customer concentration risk, with top 10 customers generating 57.59% of product sales in FY26 without long-term purchase agreements.
- High geographic concentration of manufacturing units and R&D facilities located exclusively in Madhya Pradesh.
- Heavy reliance on imported raw materials and key starting materials, particularly from China (23.88% of FY26 total expenses).
Financial Performance
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets (₹ Cr.) | 1,780.79 | 1,579.65 | 1,294.79 |
| Revenue (₹ Cr.) | 872.26 | 755.98 | 723.33 |
| PAT (₹ Cr.) | 109.9 | 96.79 | 100.06 |
| Net Worth (₹ Cr.) | 1,149.73 | 814.89 | 715.05 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Symbiotec Pharmalab | 5.35 | 51.73 | 9.48% | 1,149.73 |
| Laurus Labs Limited | 18.5 | 89.91 | 16.77% | 98.09 |
| Cohance Lifesciences | 4.45 | 297.39 | 5.05% | 102.23 |
Subscription Details
No daily bids available.
No subscription statistics available.
Company Details
- Symbiotec Pharmalab Limited
- 385/2, Pigdamber, Rau, Mhow, Indore 453 331, Madhya Pradesh, India
- +91 731 667 6405
- secretarial@symbiotec.com
- https://www.symbiotec.com/
Registrar Details
- MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)
- +91 810 811 4949
- symbiotecpharmalab.ipo@in.mpms.mufg.com
- https://in.mpms.mufg.com/
Frequently Asked Questions
What does Symbiotec Pharmalab Limited do?
What are the IPO dates for Symbiotec Pharmalab IPO?
What is the price band and minimum investment for Symbiotec Pharmalab IPO?
What is the total issue size of Symbiotec Pharmalab IPO?
What is the tentative listing date for Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO News & Updates
Follow the latest updates for Symbiotec Pharmalab IPO, including grey market moves and allotment news.
Symbiotec Pharmalab IPO IPO Pages
Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.
Symbiotec Pharmalab IPO Details
Issue size, price, financials, and company info
Symbiotec Pharmalab IPO GMP
Live grey market premium and listing estimate
Symbiotec Pharmalab IPO Subscription
QIB, NII, Retail, SHNI and BHNI subscription
Symbiotec Pharmalab IPO Allotment
Allotment date, chances, and check by PAN
Symbiotec Pharmalab IPO Review
SWOT, strengths, risks, and IPO review
Symbiotec Pharmalab IPO FAQ
Common questions on dates, GMP, and allotment
Symbiotec Pharmalab IPO Registrar
Registrar website and how to check allotment
Symbiotec Pharmalab IPO Timeline
Open, close, allotment, and listing dates
Symbiotec Pharmalab IPO News
Updates, blogs, and latest IPO news
Sources
We match Symbiotec Pharmalab IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.
- SEBIRules for IPO allotment and disclosures in India
- NSEExchange notices, bidding data, and listing updates
- BSEExchange notices and IPO allotment check tools
- RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
- MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)Official site to check allotment status for this IPO
Also read our Editorial Policy, How GMP is calculated, and How allotment chances work.
Reviewed by
Dinesh Agrawal · Lead IPO Analyst
15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.